| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
Correspondence: For correspondence or reprints contact: Hans J. Wester, PhD, Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Ismaningerstr. 22, D-81675 Munich, Germany.
ABSTRACT
The aim of the study was to develop a simple 18F-labeled amino acid as a PET tracer for cerebral and peripheral tumors. O-(2-[18F]fluoroethyl)-L-tyrosine (L-[18F]FET)was synthesized and biologically evaluated. Results of the first human PET study are reported. Methods: No carrier added (n.c.a.) and D-[18F]FET were prepared by 18F-fluoroethylation of L- and D-tyrosine in a two-step procedure. Biodistribution studies were performed in mice. The metabolic fate of L-[18F]FET was investigated in plasma, brain, tumor and pancreatic tissue samples using chromatographic procedures. Tumor uptake studies were performed in mammary carcinoma-bearing mice and in mice with the colon carcinoma SW 707. In a human PET study, a 59-y-old man with a recurrent astrocytoma was imaged using n.c.a. L-[18F]FET. Results: Synthesis of [18F]FET was accomplished in about 50 min with an overall radiochemical yield of 40%. The uptake of L-[18F]FET in the brain of mice reached a level >2% ID/g between 30 and 60 min postinjection. The brain uptake of the D-isomer was negligible, indicating blood-brain barrier penetration by a specific amino acid transport system. L-[18F]FET is not incorporated into proteins. High-performance liquid chromatography (HPLC) analysis of brain, pancreas and tumor homogenates as well as plasma samples of mice at 10, 40 or 60 min postinjection showed only unchanged L-[18F]FET. Activity uptake in the bone did not exceed 2% ID/g at 40 min postinjection. The brain uptake of L-[18F]FET in mice bearing mammary carcinomas and colon carcinomas reached 7.1% ± 1.2% ID/g and 6.4% ± 1.7% ID/g 1h postinjection, respectively. In the first human study, L-[18F]FET-PET allowed a clear delineation of a recurrent astrocytoma. Thirty-five minutes postinjection, the tumor-to-cortex ratio was >2.7. A tumor-to-blood ratio >1.5 was reached at 30 min postinjection and continued to increase. No significant activity accumulation was observed in peripheral organs after approximately 40 min postinjection. Conclusion: The high in vivo stability of L-[18F]FET, its fast brain and tumor uptake kinetics, its low accumulation in nontumor tissue and its ease of synthesis strongly support further evaluation of L-[18F]FET as an amino acid tracer for cerebral and peripheral tumors.
Key Words: PET • 18F • amino acids • 18F-fluoroethyltyrosine • FET • brain tumor
This article has been cited by other articles:
|
|
 |
|
  C. Plathow and W. A. Weber Tumor Cell Metabolism Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 43S - 63S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Stadlbauer, O. Prante, C. Nimsky, E. Salomonowitz, M. Buchfelder, T. Kuwert, R. Linke, and O. Ganslandt Metabolic Imaging of Cerebral Gliomas: Spatial Correlation of Changes in O-(2-18F-Fluoroethyl)-L-Tyrosine PET and Proton Magnetic Resonance Spectroscopic Imaging J. Nucl. Med., May 1, 2008; 49(5): 721 - 729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. W. Floeth, M. Sabel, G. Stoffels, D. Pauleit, K. Hamacher, H.-J. Steiger, and K.-J. Langen Prognostic Value of 18F-Fluoroethyl-L-Tyrosine PET and MRI in Small Nonspecific Incidental Brain Lesions J. Nucl. Med., May 1, 2008; 49(5): 730 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Haase, R. Bergmann, F. Fuechtner, A. Hoepping, and J. Pietzsch L-Type Amino Acid Transporters LAT1 and LAT4 in Cancer: Uptake of 3-O-Methyl-6- 18F-Fluoro-L-Dopa in Human Adenocarcinoma and Squamous Cell Carcinoma In Vitro and In Vivo J. Nucl. Med., December 1, 2007; 48(12): 2063 - 2071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Salber, G. Stoffels, D. Pauleit, A.-M. Oros-Peusquens, N. J. Shah, P. Klauth, K. Hamacher, H. H. Coenen, and K.-J. Langen Differential Uptake of O-(2-18F-Fluoroethyl)-L-Tyrosine, L-3H-Methionine, and 3H-Deoxyglucose in Brain Abscesses J. Nucl. Med., December 1, 2007; 48(12): 2056 - 2062. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Wyss, S. Hofer, M. Hefti, E. Bartschi, C. Uhlmann, V. Treyer, and U. Roelcke Spatial Heterogeneity of Low-Grade Gliomas at the Capillary Level: A PET Study on Tumor Blood Flow and Amino Acid Uptake J. Nucl. Med., July 1, 2007; 48(7): 1047 - 1052. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Wester Nuclear Imaging Probes: from Bench to Bedside Clin. Cancer Res., June 15, 2007; 13(12): 3470 - 3481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. W. Floeth, D. Pauleit, M. Sabel, G. Stoffels, G. Reifenberger, M. J. Riemenschneider, P. Jansen, H. H. Coenen, H.-J. Steiger, and K.-J. Langen Prognostic Value of O-(2-18F-Fluoroethyl)-L-Tyrosine PET and MRI in Low-Grade Glioma J. Nucl. Med., April 1, 2007; 48(4): 519 - 527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Wyss, N. Spaeth, G. Biollaz, J. Pahnke, P. Alessi, E. Trachsel, V. Treyer, B. Weber, D. Neri, and A. Buck Uptake of 18F-Fluorocholine, 18F-FET, and 18F-FDG in C6 Gliomas and Correlation with 131I-SIP(L19), a Marker of Angiogenesis J. Nucl. Med., April 1, 2007; 48(4): 608 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Weber Positron Emission Tomography As an Imaging Biomarker J. Clin. Oncol., July 10, 2006; 24(20): 3282 - 3292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Chen, D. H.S. Silverman, S. Delaloye, J. Czernin, N. Kamdar, W. Pope, N. Satyamurthy, C. Schiepers, and T. Cloughesy 18F-FDOPA PET Imaging of Brain Tumors: Comparison Study with 18F-FDG PET and Evaluation of Diagnostic Accuracy J. Nucl. Med., June 1, 2006; 47(6): 904 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. W. Floeth, D. Pauleit, M. Sabel, G. Reifenberger, G. Stoffels, W. Stummer, F. Rommel, K. Hamacher, and K.-J. Langen 18F-FET PET Differentiation of Ring-Enhancing Brain Lesions J. Nucl. Med., May 1, 2006; 47(5): 776 - 782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tsukada, K. Sato, D. Fukumoto, S. Nishiyama, N. Harada, and T. Kakiuchi Evaluation of D-Isomers of O-11C-Methyl Tyrosine and O-18F-Fluoromethyl Tyrosine as Tumor-Imaging Agents in Tumor-Bearing Mice: Comparison with L- and D-11C-Methionine J. Nucl. Med., April 1, 2006; 47(4): 679 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Popperl, F. W. Kreth, J. Herms, W. Koch, J. H. Mehrkens, F. J. Gildehaus, H. A. Kretzschmar, J. C. Tonn, and K. Tatsch Analysis of 18F-FET PET for Grading of Recurrent Gliomas: Is Evaluation of Uptake Kinetics Superior to Standard Methods? J. Nucl. Med., March 1, 2006; 47(3): 393 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Pauleit, A. Zimmermann, G. Stoffels, D. Bauer, J. Risse, M. O. Fluss, K. Hamacher, H. H. Coenen, and K.-J. Langen 18F-FET PET Compared with 18F-FDG PET and CT in Patients with Head and Neck Cancer J. Nucl. Med., February 1, 2006; 47(2): 256 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Pauleit, G. Stoffels, W. Schaden, K. Hamacher, D. Bauer, L. Tellmann, H. Herzog, S. Broer, H. H. Coenen, and K.-J. Langen PET with O-(2-18F-Fluoroethyl)-L-Tyrosine in Peripheral Tumors: First Clinical Results J. Nucl. Med., March 1, 2005; 46(3): 411 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pauleit, F. Floeth, K. Hamacher, M. J. Riemenschneider, G. Reifenberger, H.-W. Muller, K. Zilles, H. H. Coenen, and K.-J. Langen O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas Brain, March 1, 2005; 128(3): 678 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bergmann, J. Pietzsch, F. Fuechtner, B. Pawelke, B. Beuthien-Baumann, B. Johannsen, and J. Kotzerke 3-O-Methyl-6-18F-Fluoro-L-Dopa, a New Tumor Imaging Agent: Investigation of Transport Mechanism In Vitro J. Nucl. Med., December 1, 2004; 45(12): 2116 - 2122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Spaeth, M. T. Wyss, B. Weber, S. Scheidegger, A. Lutz, J. Verwey, I. Radovanovic, J. Pahnke, D. Wild, G. Westera, et al. Uptake of 18F-Fluorocholine, 18F-Fluoroethyl-L-Tyrosine, and 18F-FDG in Acute Cerebral Radiation Injury in the Rat: Implications for Separation of Radiation Necrosis from Tumor Recurrence J. Nucl. Med., November 1, 2004; 45(11): 1931 - 1938. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-J. Langen and S. Broer Molecular Transport Mechanisms of Radiolabeled Amino Acids for PET and SPECT J. Nucl. Med., September 1, 2004; 45(9): 1435 - 1436. [Full Text] [PDF]
|
|
|
|
|
|
D. Pauleit, F. Floeth, L. Tellmann, K. Hamacher, H. Hautzel, H.-W. Muller, H. H. Coenen, and K.-J. Langen Comparison of O-(2-18F-Fluoroethyl)-L-Tyrosine PET and 3-123I-Iodo-{alpha}-Methyl-L-Tyrosine SPECT in Brain Tumors J. Nucl. Med., March 1, 2004; 45(3): 374 - 381. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. Westera and P. A. Schubiger Functional Imaging of Physiological Processes by Positron Emission Tomography Physiology, August 1, 2003; 18(4): 175 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Shikano, K. Kawai, L. G. Flores II, R. Nishii, N. Kubota, N. Ishikawa, and A. Kubodera An Artificial Amino Acid, 4-Iodo-L-meta-Tyrosine: Biodistribution and Excretion via Kidney J. Nucl. Med., April 1, 2003; 44(4): 625 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Weber, S. Dick, G. Reidl, B. Dzewas, R. Busch, H.-J. Feldmann, M. Molls, C. B. Lumenta, M. Schwaiger, and A. L. Grosu Correlation Between Postoperative 3-[123I]Iodo-L-{alpha}-Methyltyrosine Uptake and Survival in Patients with Gliomas J. Nucl. Med., August 1, 2001; 42(8): 1144 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Jager, W. Vaalburg, J. Pruim, E. G.E. de Vries, K.-J. Langen, and D. A. Piers Radiolabeled Amino Acids: Basic Aspects and Clinical Applications in Oncology J. Nucl. Med., March 1, 2001; 42(3): 432 - 445. [Abstract] [Full Text]
|
|
|
|
|
|
J. R. Ballinger Local and Distant Effects of Radiotherapy on FDG Accumulation in Bone Marrow J. Nucl. Med., December 1, 2000; 41(12): 2036 - 2037. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
